News

Managed Healthcare Executive4d
Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients
A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...
BioPharma Dive7h
Gene therapy faces fresh uncertainty as two more top FDA officials depart
The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about ...
Gene editors steady despite latest leadership shake-up at FDA
Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research ...
BioSpace2d
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics
Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...
Why Sarepta Therapeutics (SRPT) Stock Is Down Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a ...
Sarepta crashes after second death linked to Roche-partnered Elevidys
Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...
Stocktwits on MSN4d
Sarepta Pauses DMD Gene Therapy Trial After Second Death; Retail Traders Brush Off Risk
Retail investor chatter around Sarepta Therapeutics surged on Sunday after the company announced it had suspended shipments ...